Successful treatment of pure red cell aplasia with high-dose dexamethasone after ABO-incompatible allogeneic hematopoietic stem cell transplantation

Hematol Oncol Stem Cell Ther. 2018 Mar;11(1):44-46. doi: 10.1016/j.hemonc.2017.08.004. Epub 2017 Oct 18.

Abstract

The literature reports an incidence of Pure Red Cell Aplasia (PRCA) ranging from 6-30% of all cases of ABO-incompatible HSCT. Although most patients resolve spontaneously after withdrawal immunosuppression, some of them require more aggressive treatment to manage this condition.

Keywords: Aplastic anemia; Dexamethasone; Hematopoietic stem cell transplantation; Pure red cell aplasia.

MeSH terms

  • ABO Blood-Group System / immunology*
  • Adult
  • Allografts
  • Anemia, Aplastic* / blood
  • Anemia, Aplastic* / immunology
  • Anemia, Aplastic* / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Immunosuppression Therapy / adverse effects*
  • Immunosuppression Therapy / methods
  • Male
  • Red-Cell Aplasia, Pure* / etiology
  • Red-Cell Aplasia, Pure* / immunology
  • Red-Cell Aplasia, Pure* / pathology
  • Red-Cell Aplasia, Pure* / therapy

Substances

  • ABO Blood-Group System